Business
PRTC to Present at Jefferies 2018 in London
PRTC to Present at Jefferies 2018 in London.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 5533G PureTech Health PLC 07 November 2018 \n\n7 November 2018\n \nPureTech Health plc\n \nPureTech Health to Present at Jefferies 2018 London Healthcare Conference\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced that Joep Muijrers, PhD, Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in London on Thursday, 15 November at 10:00 AM GMT. A webcast of the presentation will be available at http://puretechhealth.com/investors under the Reports and Presentations tab.\n \nAbout PureTech Health\nPureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insights into the connection between the individual components of these systems and the resulting role in many chronic diseases, which have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.\n \nPureTech Health is advancing a rich pipeline of innovative therapies across two divisions: the Affiliates division and the Internal division. Its Affiliates division includes two product candidates that have been filed with the US Food and Drug Administration (FDA) for review and several other novel clinical and pre-clinical programmes. These affiliates are developing ground-breaking platforms and therapeutic candidates in collaboration with some of the world's leading experts.\n \nPureTech's Internal division is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programmes leverage the transport and biodistribution of various immune system components for the targeted treatment of diseases with major unmet needs, including cancers, autoimmune diseases, and neuroimmune disorders.\n \nFor more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.\n \nForward Looking Statement\nThis...